News

New research led by investigators at Beth Israel Deaconess Medical Center (BIDMC) helps explain the recent reversal in cardiovascular mortality among this population and underscores the need to address the social determinants of health that...

This is the largest study of its kind comparing outcomes of strokes from a blood clot from the heart in atrial fibrillation patients treated with LAAC versus blood thinners. 

A groundbreaking study recently published in JAMA indicates that aspirin may not be necessary as part of an antithrombotic regimen for patients with a fully magnetically levitated left ventricular assist device (LVAD).

The first clinical trial to challenge the routine implantation of a defibrillator in myocardial infarction survivors with heart failure has enrolled its first patient.

Manufacturing of the device for U.S. distribution is already underway, and Medtronic hopes to make it widely available soon to physicians and healthcare systems.

The S.M.A.R.T. RADIANZ™ Vascular Stent System, specifically engineered for radial access, was approved for use in the United States by the FDA in February 2022, and in Japan by PMDA in March 2022.

Available in 14 and 18 Fr. sizes, the MANTA™ Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20 Fr. devices or sheaths (12-25 Fr. O.D.) in endovascular procedures.

The guidewire’s functionality is designed to allow for comprehensive data collection and analysis and facilitates data necessary for novel Artificial Intelligence (AI) decision-making tools.

Study participants were randomly assigned to either 2.4 mg of semaglutide (FDA-approved dose for weight management) or a placebo 1x/week, which is higher than the FDA-approved semaglutide dose limit for Type 2 diabetes of 2.0 mg/week.

ORBITA-2 is the first sham-controlled trial to confirm the benefit of percutaneous coronary intervention (PCI) for patients with stable ischemic heart disease.